Small Molecules
12 January 2015
Arena Pharmaceuticals Initiates Phase 2 Clinical Trial Evaluating Ralinepag for Pulmonary Arterial Hypertension12 January 2015
Debiopharm Group™ Regains Full Rights to Alisporivir Program11 January 2015
Zydus begins Phase – III study of Saroglitazar in NASH, a liver disease caused by obesity, diabetes and lipid disorders11 January 2015
CoMentis and Anvyl Announce the Initiation of Clinical Trials for APN1125 for the Treatment of Schizophrenia11 January 2015
Chipscreen Biosciences Announces CFDA Approval of Chidamide (Epidaza) for PTCLs in China9 January 2015
MerLion’s Finafloxacin Shows Positive Phase 2 Results in Complicated Urinary Tract Infections8 January 2015
GW Pharmaceuticals and Otsuka Announce Results in First of Three Sativex(R) Phase 3 Cancer Pain Trials8 January 2015
Cleave Biosciences Initiates Phase 1 Clinical Trial of CB-5083 in Patients with Advanced Solid Tumors8 January 2015
CytRx Announces Positive Interim Phase 2 Aldoxorubicin Results as a Treatment for HIV-Related Kaposi’s Sarcoma (KS)8 January 2015
Infinity Reports Topline Results from Phase 2 Study of Duvelisib in Rheumatoid Arthritis8 January 2015
Melinta Therapeutics’ Lead Candidate Delafloxacin Yields Positive Top-Line Results in Phase 3 Study in Patients with ABSSSI8 January 2015
Novartis announces robust Phase III results for QVA149 and NVA237 and submits regulatory applications to US FDA7 January 2015
New Study Demonstrates Diabetic Nephropathy Prevention and Reversal Using Jenrin Discovery’s Novel CB1 Inverse Agonist JD-5037News Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
SubscribeNewsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
SubscribeFeatured reports